Funding news · Sep 30, 2026
Leadsynbio (引航生物) Raises CNY 450M Series C+ for Synthetic-Biology Manufacturing
Leadsynbio (引航生物) Raises CNY 450M Series C+
Suzhou Leadsynbio Technology (引航生物), a synthetic-biology company focused on industrial-scale biosynthesis, has raised CNY 450 million in Series C+ funding. The round was announced on September 30, 2026.
What the Company Does
Leadsynbio develops proprietary biosynthesis routes and manufactures pharmaceutical ingredients and nutrition products at industrial scale. Its portfolio spans three main categories:
- Active pharmaceutical ingredients and intermediates, including florfenicol
- Human-nutrition ingredients, including NMN, NAD and 25-hydroxyvitamin D3
- Animal-nutrition products
The company operates GMP bio-manufacturing plants in Hunan and Anhui, alongside R&D centers in Suzhou and the United States. It is headquartered in Suzhou Industrial Park and sells to customers across global markets.
The Round
| Detail | Value |
|---|---|
| Round type | Series C+ |
| Amount | CNY 450 million |
| Announced | September 30, 2026 |
| Lead investor | Not disclosed |
Investor Group
The round drew participation from a group of investors spanning regional industrial funds and venture capital:
- Yuanfeng Capital (园丰资本)
- Hunan Caixin Industrial Fund (湖南财信产业基金)
- Yuanhe Holding (元禾控股)
- Su Chuangtou (苏创投)
- Hunan Caixin (湖南财鑫)
- Su Chantou (苏产投)
- Chuangke Zhisheng (创客智盛)
No single lead investor was named for the round.
Why It Matters
Leadsynbio sits at the intersection of synthetic biology and industrial manufacturing — a capital-intensive combination that requires both process-development expertise and physical production capacity. The company's model is built around proprietary biosynthesis routes rather than conventional chemical synthesis, which it applies across pharmaceutical, human-nutrition and animal-nutrition end markets.
The presence of multiple Hunan-linked industrial funds in the round is notable given the company's GMP manufacturing footprint in Hunan. Suzhou-area investors, including Yuanhe Holding and Su Chuangtou, reflect the company's base in Suzhou Industrial Park.
Scale and Positioning
With GMP plants in two provinces and R&D operations in both China and the US, Leadsynbio has built out an integrated development-and-manufacturing footprint. Its product list targets several distinct demand pools:
- Pharmaceutical ingredients such as florfenicol and intermediates, serving drug manufacturers
- Human nutrition via NMN, NAD and 25-hydroxyvitamin D3, ingredients associated with the health and wellness segment
- Animal nutrition, addressing feed and livestock markets
Selling into global markets means the company must meet the regulatory and quality standards of multiple jurisdictions — a barrier that favors manufacturers with established GMP infrastructure.
What to Watch
The Series C+ designation indicates an extension of the company's prior Series C financing rather than a new stage. For an acquisition-oriented reader, the key questions are how the new capital is allocated across the Hunan and Anhui manufacturing sites versus R&D, and whether the company's nutrition-ingredient lines scale as quickly as its pharmaceutical business.
Leadsynbio has not disclosed a lead investor, valuation, or specific use of proceeds for the round.